Office of Cannabis Management required to establish limits on the total THC in cannabis flower and cannabis products; addition of ingredients to impart a taste or smell to cannabis products intended to be consumed through the inhalation of smoke, vapor, or aerosol prohibited; warnings about cannabis consumption required to include a warning regarding cancer; and advertisements prohibited that promote the co-consumption of alcohol and cannabis.
HF755 would direct the Minnesota Office of Cannabis Management to set limits on total THC in cannabis flower, cannabis products, and hemp-derived consumer products. It also tightens product approval rules by prohibiting certain cannabis items that resemble candy or child-appealing products, contain synthetic cannabinoids, are made by adding cannabinoids to finished foods like candy or snacks, or are intended for inhalation but include added flavors or scents other than cannabis. The bill further bars approval of edible cannabis and lower-potency hemp products containing non-FDA-approved food ingredients.
The bill also expands required consumer information. Cannabis businesses and related retailers would have to provide customers and patients with information on impairment, timing of impairment, side effects, adverse effects, cancer risk, safe-use warnings, poison control contact information, and substance use disorder treatment resources. This information could be posted on-site or provided in a separate pamphlet or document, and may also be included on product labels if the office allows.
On the advertising side, HF755 adds restrictions on cannabis and hemp advertising, including a prohibition on ads that promote drinking alcohol while using cannabis, depict underage consumption, use child-appealing imagery, show alcohol use, or omit required impairment and health-risk warnings. The bill amends Minnesota Statutes sections 342.06, 342.63, and 342.64, so its legal effect would be to impose additional product-safety, labeling, warning, and marketing limits on cannabis and hemp businesses operating in Minnesota.
The overall sentiment reflected in the bill text is precautionary and public-health oriented, emphasizing youth protection, product safety, and consumer warnings. Because there are no recorded committee transcripts or votes in the provided material, there is no documented floor or committee debate to indicate broader support or opposition. The bill’s structure suggests a regulatory tightening rather than a major expansion of cannabis access.
The main points of contention likely concern how far the state should go in regulating THC potency, product formulation, and advertising, especially for hemp-derived products and inhalable cannabis products. Businesses in the cannabis and hemp sectors could view the bill as burdensome or overly restrictive, while public-health advocates would likely support the added limits, warning requirements, and restrictions on child-appealing products and alcohol-cannabis co-marketing.
HF755 would amend Minnesota’s cannabis regulatory framework by giving the Office of Cannabis Management authority to set THC limits, by narrowing which cannabis and hemp products may be approved for retail sale, and by imposing new labeling, warning, and advertising restrictions. It would affect cannabis businesses, hemp businesses, retailers, and medical cannabis combination businesses, while also shaping the product standards applicable to cannabis flower, cannabis products, lower-potency hemp edibles, and hemp-derived consumer products.
The bill appears to have a generally cautious, public-health-focused tone, emphasizing consumer warnings, youth protection, and limits on product potency and marketing. No committee testimony or vote record was provided, so there is no direct evidence of legislative support or opposition in the available materials.
Likely areas of contention include the proposed THC limits, the prohibition on flavored inhalable products, restrictions on hemp-derived consumer products, and the ban on advertisements promoting alcohol-cannabis co-consumption. Cannabis and hemp industry stakeholders may argue the bill is overly restrictive or difficult to comply with, while supporters are likely to emphasize preventing youth appeal, reducing misuse, and improving health warnings.